Skip to main content

B-cell Malignancy clinical trials at University of California Health

4 in progress, 3 open to eligible people

Showing trials for
  • Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

    open to eligible people ages 18 years and up

    Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    at UCLA UCSD

  • AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    open to eligible people ages 18 years and up

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    at UC Irvine

  • Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

    open to eligible people ages 18 years and up

    B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 100 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants will receive one of two oral doses of ABBV-525, until the recommended phase 2 dose (RP2D) is determined. In part 3 (dose expansion), participants will receive the RP2D oral dose of ABBV-525. The estimated duration of the study is up to 64 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

    at UCLA

  • CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

    Sorry, in progress, not accepting new patients

    This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.

    at UCSF

Our lead scientists for B-cell Malignancy research studies include .

Last updated: